Evidence map›Paper›PMID 27978872›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2016

[Primary Application of Radiofrequency Ablation after Locally Progression of
EGFR-TKIs in Non-small Cell Lung Cancer].

Baodong Liu, Yuanbo Li, Mu Hu, Lei Liu, Kun Qian, Ruotian Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Baodong LiuDepartment of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Yuanbo LiDepartment of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Mu HuDepartment of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Lei LiuDepartment of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Kun QianDepartment of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Ruotian WangDepartment of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is one of the foundamental treatment for non-small cell lung cancer (NSCLC) with EGFR mutation, however some patients might develop locally progression in primary site. The aim of this study is to assess the clinical application of radiofrequency ablation after locally progression of NSCLC while receving EGFR-TKIs.

methodsTwenty-eight eligible NSCLC patients were enrolled. Efficacy and Safety data of radiofrequency ablation followed by EGFR-TKIs or chemotherapy were collected.

resultsNone of patients had died during peri-operation period. The average follow-up time was 17.25 months. Locally progression rate was 10.7% (3/28), and locally progression time was 16.6 months. The average progression-free survival was (24.55±5.36) (95%CI:14.04-35.05), and the average overall survival was (25.57±5.45)(95%CI:14.88-36.27). Patients were divided into EGFR-TKIs group and chemotherapy group after radiofrequency ablation. The average progression-free survival of the two groups were (27.82±7.58)(95%CI:12.97-42.68) and (17.88±3.76)(95%CI:10.52-25.25)(P>0.05) respectively. The average OS (overall survival) was (29.42±7.68)(95%CI:14.36-44.48) and (18.44±3.87)(95% CI:14.89-36.27)(P>0.05) in two groups.

conclusionsRadiofrequency ablation combined with EGFR-TKIs or chemotherapy could prolong progression-free survival and overall survival of EGFR mutant NSCLC patients who had developed locally progression in primary site during EGFR-TKIs treatment.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCombined Modality TherapyDisease-Free SurvivalErbB ReceptorsFemaleHumansLung NeoplasmsMaleMiddle AgedMutationProtein Kinase InhibitorsPulsed Radiofrequency TreatmentTreatment OutcomeErbB ReceptorsProtein Kinase Inhibitors

Identifiers

PMID27978872
PMCPMC5973449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.